Wave Life Sciences Appoints Monika Vnuk CBO
Analysis based on 6 articles · First reported Sep 22, 2026 · Last updated Sep 22, 2026
The appointment of a seasoned business development executive signals potential for future licensing, partnership, and value-creating transactions, which modestly supports investor sentiment toward Wave Life Sciences. The immediate market reaction was positive, with Wave shares rising 2.44 percent on the Nasdaq, though the impact is limited to a single small-cap biotech and has negligible broader market effect.
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on RNA medicines, announced on September 22, 2026 the appointment of Monika Vnuk, MD, as Chief Business Officer, a newly created leadership role. Dr. Vnuk will join Wave's executive team and lead business development, corporate development, and alliance management. She brings substantial experience from prior roles, including Senior Vice President and Global Head of Partnering and Business Development at Sanofi, Managing Director at Blackstone Life Sciences, and more than a decade at Pfizer in senior business development roles, where she led the negotiation of the partnership with BioNTech for global co-development and distribution of COVID-19 vaccines. She also worked in investment banking at Bank of America and at Oxford Bioscience Partners. Wave CEO Paul Bolno welcomed Dr. Vnuk, citing her breadth of experience in global business development and strategic asset financing as meaningful for advancing Wave's pipeline and supporting its next phase of growth. In connection with her appointment, Dr. Vnuk received a stock option to purchase 375,000 shares of Wave common stock, granted on September 21, 2026 at an exercise price of $4.25 per share, vesting over four years. Following the announcement, Wave shares traded up 2.44 percent at $4.3586 on the Nasdaq.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard